Acumen Pharmaceuticals Inc

NASDAQ ABOS

Data sourced from iex and EODHD
Download Data

Acumen Pharmaceuticals Inc Return on Investment (ROI) for the year ending December 31, 2023: -21.90%

Acumen Pharmaceuticals Inc Return on Investment (ROI) is -21.90% for the year ending December 31, 2023, a 65.74% change year over year. Return on investment (ROI) measures the profitability of a company relative to its total investments. It is calculated by dividing the net income by the total investments. This ratio provides insights into the overall return generated by the company's investment activities. A higher ROI indicates better profitability and efficient capital allocation.
  • Acumen Pharmaceuticals Inc Return on Investment (ROI) for the year ending December 31, 2022 was -63.90%, a 63.53% change year over year.
  • Acumen Pharmaceuticals Inc Return on Investment (ROI) for the year ending December 31, 2021 was -175.21%.
NASDAQ: ABOS

Acumen Pharmaceuticals Inc

CEO Mr. Daniel J. O'Connell M.B.A.
IPO Date July 1, 2021
Location United States
Headquarters 427 Park Street, Charlottesville, VA, United States, 22902
Employees 51
Sector Healthcare
Industry Biotechnology
Description

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers. The company has a license agreement with Lonza Sales AG to manufacture and commercialize sabirnetug; and a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of sabirnetug. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.

Similar companies

DAWN

Day One Biopharmaceuticals Inc

NA

NA

StockViz Staff

September 19, 2024

Any question? Send us an email